• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Global Biosciences Co. Selects ValGenesis VLMS

    Eisai Appoints Chief Clinical Officer of Oncology Biz

    Nexelis Acquires GSK Vax Lab in Marburg

    Bone Therapeutics, Rigenerand Ink Cell Therapy Deal

    NovaQuest Private Equity Acquires CoreRx
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Lonza to Exit Pharma Softgels and Liquid-Filled Hard Capsules

    Cognate BioServices Announces Major Expansion

    Sanofi Unveils EUROAPI as Name of New European API Company

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe

    Schreiner MediPharm Joins DoseID Consortium
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Global Biosciences Co. Selects ValGenesis VLMS

    Nexelis Acquires GSK Vax Lab in Marburg

    The Future of Clinical Trials Series: Part I

    JS Bio and Etta Biotech Advancing Partnership

    Intravacc Completes Project for Provention Bio’s Vax Candidate
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    CDMO Cognate BioServices Teams Up with L7 Informatics
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    PCI Pharma Services

    Reed-Lane

    Syngene

    Alcami

    Cytovance Biologics
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Emergent BioSolutions

    Alcami

    Aphena Pharma Solutions

    Baxter BioPharma Solutions

    Flow Sciences
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Expert's Opinion

    Five Ways to Enhance Clinical Operational Efficiencies Utilizing AI

    The proven promise and huge potential of using AI and ML to accelerate drug discovery.

    Five Ways to Enhance Clinical Operational Efficiencies Utilizing AI
    Related CONTENT
    • Probing the Limits of Pharma’s Future
    • Better Drug Manufacturing Strategies: Custom APIs
    • Tufts CSDD Names Ken Getz New Deputy Director
    • Four Pitfalls to Avoid When Packaging Injectable Drug Products
    • Permira Funds to Acquire Cambrex in $2.4B Transaction
    Lucas Glass, Gary Shorter, and Rajneesh Patil, IQVIA10.21.19
    Artificial intelligence and machine learning tools are transforming how clinical development occurs by delivering significant time and cost efficiencies while providing better and faster insights to inform decision-making. Advances in analytics technology coupled with the availability and integration of vast amounts of healthcare data have already helped automate processes and improve data quality across dozens of clinical development efforts.

    As these tools evolve, new opportunities will continue to emerge that drive further benefits to the clinical research landscape. Applications of AI and ML in healthcare are expected to grow to nearly $8 billion by 2022, up from $667.1 million in 2016, and almost half of global life science professionals say they are either using or interested in using AI in their research.[1]

    Despite this growth, the industry continues to struggle with what these technologies are and how they work. And there is uncertainty on how to surmount the challenges required to leverage AI and ML.

    When sponsors collaborate with partners that have the necessary technical and pharmaceutical expertise, they can achieve significant time and cost savings while reducing risks and improving the quality of their research. Here are five proven areas where AI and ML can directly impact operational efficiencies:

    1. Study design
    Poor study design has a catastrophic impact on the cost, efficiency and success potential of clinical trials. Leveraging vast healthcare data sets, AI, ML and natural language processing tools can be used to assess and select optimal primary and secondary endpoints during study design to ensure the most relevant protocols are defined for regulators, payers and patients. This helps to optimize the study design by informing ideal strategies for host countries and sites, enrollment models, patient recruitment and start-up plans.

    Better study design leads to more predictable results, reduced cycle time for protocol development, fewer protocol amendments and higher efficiencies throughout a study. It also results in improved recruitment rates and fewer non-enrolling sites. These improvements facilitate realistic and accurate planning and increase chances of success.

    2. Site identification and patient recruitment
    Identifying trial sites that have access to enough patients who meet inclusion/exclusion criteria is an ongoing challenge. As studies target more specific populations, recruiting goals become even harder to achieve, which drives costs up, increases timelines and raises the risk of failure. According to Tufts Center for the Study of Drug Development, nearly half of all sites miss enrollment targets.

    AI and ML can mitigate these risks by identifying and suggesting the sites with the highest recruitment potential and suggesting appropriate recruitment strategies. This involves mapping patient populations and proactively targeting sites with high predicted potential to deliver the most patients — before a single site is opened — and identifying the best avenues to recruit them. This means sponsors can open fewer sites, accelerate recruiting and reduce the risk of under-enrollment.

    3. Pharmacovigilance
    To ensure drug safety, massive amounts of structured and unstructured data must be integrated and reviewed. PV units that seek to harness the power of this data find that AI and ML technologies address many of the challenges they face by providing new levels of insight and predictive analytics. These tools can automate manual processing tasks and translate and digitize case safety reporting and adverse drug reaction documents. They can also monitor digital conversations on social media and other platforms to ensure that adverse events are promptly identified.

    Natural language processing, Optical character recognition, and deep neural networks are being used to analyze and format structured and unstructured data for faster and more efficient safety reviews.

    The insights derived from using AI for PV tasks lead to faster assessment of subject, site and study risks and overall study performance by domain experts. This allows project leads to increase efficiencies as well as patient safety.

    4. Clinical monitoring
    Tremendous manual effort is spent analyzing site risks and generating “action items” to mitigate those risks. AL and ML concepts can alleviate these pressures by assessing the risk environment and delivering predictive analytics to generate more effective clinical monitoring insights.

    Advanced analytics provide composite site rankings for holistic risk assessments, allowing for more specific identification of risks and removal of false positives. Using the composite evaluation of site risks across the study quickly shows high-risk sites, key risk indicators and site risk rank. Evaluations can also be used to proactively identify which sites are more likely to have recruitment and performance issues, or which patients are at higher risk for potential AEs. These insights facilitate faster action and avoid potential problems.

    5. Patient care
    Disease detection algorithms are now being designed to leverage medical information, such as symptoms and procedures that typically precede a diagnosis, to identify patients who are very likely to develop diseases. This allows for proactive care, as well as new recruiting insights for prodromal or early-stage disease studies and those that require treatment-naive patients.

    One area where this type of model is having a profound impact is Alzheimer’s disease research. Due to the exponential effects of a delayed AD diagnosis, much clinical research activity in AD is focused on the prodromal stage. Yet, traditional screenings for prodromal AD patients deliver only a 20 percent precision rate.

    AI and ML: Augmenting the Future of Clinical Development
    The clinical development landscape is changing quickly, and sponsors need to have the best insights to make the right decisions to increase predictability, reduce time to market and improve efficiencies. By using these methods in clinical development, we can introduce change to prove — and improve — how AI-derived insights can be applied to many aspects of development.

    These technologies aren’t going to replace human expertise. But they are going to accelerate the ability to analyze the data and take meaningful action in response to create a safer, more streamlined research environment. As the volume and complexity of clinical data continue to increase and more real-world evidence is introduced, AI applications have great potential value for the clinical trial process and the pharmaceutical drug discovery industry.

    Talent, Technology and Expertise
    These technologies hold huge promise for clinical development, but that promise can only be achieved when organizations have the tools, talent and partners to leverage these technologies in relevant ways. To achieve the full potential of AI and ML in clinical development, pharma companies need partners who can provide:

    ·      Deep pharmaceutical knowledge and domain expertise. This expertise should include in-depth understanding of healthcare data for insightful analyses, understanding of global regulatory environments, payer expectations, physician and patient behavior and therapeutic knowledge.
    ·      State-of-the-science AI and ML technologies. The solution should be capable of mining multiple data sets with speed and scale to identify high-level global and regional trends, as well as detailed physician- and patient-level insights while applying rigor through the GxP Software Development Life Cycle approach to produce top quality models.

    ·      Data analytics and machine learning experts. The customer team should include technical experts who are skilled in crafting machine learning algorithms relevant to the clinical development process.

    ·      Access to vast healthcare data sets. Machine learning algorithms are only as good as the data they can access. The most effective platforms will provide access to multiple global healthcare databases, including prescription data, EMRs, pharma sales data and patient and disease trend data that are updated regularly.

    ·      The ability to integrate these disparate data sets. Many healthcare data sets are unstructured or inconsistent in form and formatting, making them difficult to analyze. A good partner will have strategies in place to clean the data, so the algorithms can interpret results and translate them into actionable insights that drive better results.

    As the life sciences industry continues to evolve, more sophisticated analytics capabilities are required to advance the understanding of human health through better, more insightful decisions. Integrating human science with breakthroughs in data science and technology provides more relevancy and precision to decision-makers. It can transform how patients are diagnosed and treated, with minimal errors. It can help identify patients — faster and maybe even before they are patients.

    The proven promise and huge potential of using AI and ML to accelerate drug discovery while cutting costs and risks is a tremendous catalyst for innovation. By continuing to leverage data, intelligence, analytics and domain expertise, there is an enormous opportunity for the industry to fundamentally transform the clinical development landscape in ways that will greatly benefit patients, sponsors, payers and physicians alike.


    [1] Source: Accenture, “Artificial Intelligence: Healthcare’s New Nervous System,” https://www.accenture.com/au-en/insight-artificial-intelligence-healthcare



     
    Lucas Glass is the Global Head of IQVIA’s Analytics Center of Excellence; responsible for researching, developing and operationalizing machine learning and data science solutions in the R&D business.






     
    Gary Shorter, Head of Artificial Intelligence, Research & Development Solutions, IQVIA. Gary Shorter holds an MSc and has served as global biostatistics lead for multiple compounds in clinical trials.







     
    Rajneesh Patil, Head of Process Design & Analytics, Centralized Monitoring Services, IQVIA. Rajneesh Patil’s expertise spans process design, project portfolio management, risk-based monitoring and advanced analytics for clinical trial applications.
    Related Searches
    • risk-based monitoring
    • machine learning
    • pharmacovigilance
    • patients
    Suggested For You
    Probing the Limits of Pharma’s Future Probing the Limits of Pharma’s Future
    Better Drug Manufacturing Strategies: Custom APIs Better Drug Manufacturing Strategies: Custom APIs
    Tufts CSDD Names Ken Getz New Deputy Director Tufts CSDD Names Ken Getz New Deputy Director
    Four Pitfalls to Avoid When Packaging Injectable Drug Products Four Pitfalls to Avoid When Packaging Injectable Drug Products
    Permira Funds to Acquire Cambrex in $2.4B Transaction Permira Funds to Acquire Cambrex in $2.4B Transaction
    Pressure BioSciences Inks Contract Services Deal Pressure BioSciences Inks Contract Services Deal
    Artificial Intelligence and Machine Learning in Healthcare Artificial Intelligence and Machine Learning in Healthcare
    Pacira Appoints Max Reinhardt as President Pacira Appoints Max Reinhardt as President
    LAST CHANCE: Participate in Tufts LAST CHANCE: Participate in Tufts' Study on the Vendor Qualification Process
    The Headhunter’s Call The Headhunter’s Call
    Risk-Based Monitoring Risk-Based Monitoring
    CROs May Get a Regulatory Boost CROs May Get a Regulatory Boost
    Cryoport, CalAmp Enter Strategic Collaboration  Cryoport, CalAmp Enter Strategic Collaboration
    Tufts CSDD Study on the Vendor Qualification Process Tufts CSDD Study on the Vendor Qualification Process
    The Pharma Supply Chain The Pharma Supply Chain

    Related Expert's Opinion

    • Clinical Trials | Drug Development | Information Technology
      Virtual Clinical Trials: The Future of Dermatology Studies

      Virtual Clinical Trials: The Future of Dermatology Studies

      COVID-19 has created lasting impacts for clinical trials and a host of benefits have arisen from the adoption of virtual and hybrid models.
      Sonja VanWye, RN, MSN, Director, Dermatology Strategy, IQVIA Biotech 01.15.21

    • Clinical Trials | Drug Development
      The Slow – But Desperately Needed – Evolution of Oncology Clinical Development Designs

      The Slow – But Desperately Needed – Evolution of Oncology Clinical Development Designs

      Appropriate adaptive designs in early stages of development can accelerate timelines and reduce costs, and help focus on the most promising agents.
      Jürgen Hummel, MSc, Senior Director, Statistical Science, PPD, and Lead of PPD’s Adaptive Design Working Group 01.07.21

    • Drug Development | Industry News | Regulatory Affairs
      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      A look at EUA standards and approvals, unavoidable pitfalls, Operation Warp Speed, FDA’s use of Real-World Evidence, and a slow return to "normalcy".
      Chad Landmon, Michelle Divelbiss and Alex Alfano, Axinn, Veltrop & Harkrider LLP's Intellectual Property and Food and Drug Administration Practice Groups 01.05.21


    • Clinical Trials | Information Technology
      Life Sciences Strive for Greater Agility

      Life Sciences Strive for Greater Agility

      Embracing real-time drug safety monitoring during and post COVID will continue to propel the industry forward.
      Ronan Brown, SVP of Integrated Technology & Compliance, and Joe Rymsza, VP, Global PV & Regulatory Technology Solutions, IQVIA 12.14.20

    • Clinical Trials | Drug Development | Information Technology
      Advances in Intelligent Automation

      Advances in Intelligent Automation

      The future of medicine relies on further digital transformation and automation-enabling solutions to improve drug development and monitoring.
      Updesh Dosanjh, Practice Leader, Technology Solutions, IQVIA 12.14.20

    • Drug Development
      Navigating Uncertainty: Considerations for Life Sciences 2021

      Navigating Uncertainty: Considerations for Life Sciences 2021

      With vaccines against COVID-19 on the horizon, our focus is shifting to 2021 and the major issues life sciences companies face and reasons for optimism.
      Arda Ural , EY Americas Health Sciences and Wellness Industry Leader, Ernst & Young LLP 12.11.20


    • Information Technology | Supply Chain
      The Pandemic & The Pharma Industry: 3 Things to Know

      The Pandemic & The Pharma Industry: 3 Things to Know

      The importance of vendor contract visibility, an increase in intense legal scrutiny, and new technology for greater agility and control.
      Colin Earl, CTO at Agiloft 11.16.20

    • Clinical Trials | Information Technology
      AI and Advanced Analytics

      AI and Advanced Analytics

      Equipped with the right tools, CROs are better positioned to develop optimal protocols, rapidly identify patients to enroll, and preempt study issues.
      Paul Oliver, Medidata 11.13.20

    • Clinical Trials | Information Technology
      eCOA: Addressing Barriers to Faster Deployment in Clinical Trials

      eCOA: Addressing Barriers to Faster Deployment in Clinical Trials

      Clinical Outcome Assessments are an increasingly important tool in clinical research.
      Paul O'Donohoe, Scientific Lead, eCOA and Mobile Health, Medidata 11.13.20


    • Clinical Trials | Information Technology
      Adding Remote Site Access to Sponsor Bids: What to Know as CRO

      Adding Remote Site Access to Sponsor Bids: What to Know as CRO

      Traditional monitoring has changed, CROs should build a portfolio of remote access solutions and have them ready.
      Ryan Jones, CEO, Florence Healthcare 10.13.20

    • Drug Development
      New York City is Not Dead, Our Life Sciences Sector is Thriving

      New York City is Not Dead, Our Life Sciences Sector is Thriving

      Amid the COVID-19 pandemic, life sciences is booming in NYC!
      Sara Jane Demy, CEO & Founder, Demy-Colton 10.01.20

    • Clinical Trials | Drug Development
      How to Balance Internal and External Staff Within Outsourcing Models

      How to Balance Internal and External Staff Within Outsourcing Models

      Strategies to consider in flexed staffing models.
      John Barry, SVP, Consulting Practice and Chief Strategy Officer, PRA Health Sciences, SSD 09.22.20


    • Biologics, Proteins, Vaccines | Drug Development
      The Importance of Global Collaboration in the Fight Against COVID-19

      The Importance of Global Collaboration in the Fight Against COVID-19

      Industry continues to join forces to find new treatments for COVID-19.
      Dohyun Cho, Chief Operating Officer, Enzychem Lifesciences 09.08.20

    • Clinical Trials | Drug Development
      FDA Response to COVID-19

      FDA Response to COVID-19

      A Discussion on Protocol Amendments and Clinical Study Reports in Affected Ongoing Trials.
      Jack Modell, M.D., Vice President and Senior Medical Officer, Rho 09.03.20

    • Clinical Trials | Drug Development
      Beyond 2020: The Future of CROs

      Beyond 2020: The Future of CROs

      How will remote site access impact the CRO business?
      Ryan Jones, CEO, Florence Healthcare 08.21.20

    Trending
    • Lonza To Exit Pharma Softgels And Liquid-Filled Hard Capsules
    • Roche Canada To Invest $500M To Create 500 Jobs In Ontario
    • Grifols Begins COVID-19 Plasma Treatment Trial
    • Fujifilm To Invest $2B In US Manufacturing Site
    • Virtual Clinical Trials: The Future Of Dermatology Studies
    Breaking News
    • Global Biosciences Co. Selects ValGenesis VLMS
    • Eisai Appoints Chief Clinical Officer of Oncology Biz
    • Nexelis Acquires GSK Vax Lab in Marburg
    • Bone Therapeutics, Rigenerand Ink Cell Therapy Deal
    • NovaQuest Private Equity Acquires CoreRx
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Euromonitor Names Top Ten Trends for 2021
    Study Highlights Differences Between EPA's and DHA's Effect on Sleep
    BGG Obtains U.S. Patent on AstaZine Natural Astaxanthin for Heart Function During Exercise
    Coatings World

    Latest Breaking News From Coatings World

    IGL Coatings Launches Graphene Reinforced Dual System Ceramic Coating
    Miller Paint Declares Simple Serenity its 2021 Color of the Year
    TAUBMANS Paint by PPG Releases ‘Chromatic Joy’ Palettes
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Eitan Medical Receives FDA Clearance for Sapphire Infusion System
    Researchers Successfully ‘Fine Tune’ New Thermoplastic Biomaterial
    RSIP Vision Announces Versatile Medical Image Segmentation Tool
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Global Biosciences Co. Selects ValGenesis VLMS
    Eisai Appoints Chief Clinical Officer of Oncology Biz
    Nexelis Acquires GSK Vax Lab in Marburg
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Top Beauty Brands in the World—And Most Loved Fragrances
    P&G Reports Q2 Results
    A Lacquering Technique Makes Very Good Girl by Carolina Herrera Shine
    Happi

    Latest Breaking News From Happi

    Ross Introduces Double Cone Tumble Blender
    Colonial Chemical Announces New Facility
    Ashland Acquires Schülke & Mayr's Personal Care Business
    Ink World

    Latest Breaking News From Ink World

    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    THIMM Group Installs 1st Koenig & Bauer CorruFLEX
    Cowan Graphics Adds Fujifilm Inca OnsetX3 HS
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Domino grows installation and service teams
    ABG keeps pace with demand with recruitment drive
    Acucote expands FSC-certified portfolio
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    First Quality Launches Incognito by Prevail
    Essity Launches Reusable Underwear Product
    Honeywell Delivered 225 Million Masks in December
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    DJO Acquires Trilliant Surgical
    FDA Breakthrough Device Designation Granted to Spiderwort's Spinal Cord Technology
    Bioventus Appoints SVP of Operations
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Graphene Flagship Launches Redesigned Website

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login